PLA2G7 and coronary artery disorder: The STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy)26 and the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52)27 studies evaluated the clinical efficacy and safety of the Lp-PLA2 inhibitor (darapladib) in patients with stable CAD and ACS, respectively.